Morpholine KECH-18D Restores Drug Sensitivity and Differentially Modulates Efflux Phenotypes in Cisplatin- and Paclitaxel-Resistant Cervical Cancer Cells

Authors

DOI:

https://doi.org/10.31557/APJCB.2026.11.3.705

Keywords:

Chemoresistance, Cisplatin-resistant cells, Paclitaxel-resistant cells, Morpholine KECH-18D, Drug efflux modulation

Abstract

Background: Chemoresistance represents a major obstacle in cancer therapy, often associated with enhanced drug efflux. This study aimed to generate and characterize cisplatin-resistance in C-33A cells (C-33A RCDDP), and included, for comparison, a previously established paclitaxel-resistant subline (C-33A RPTX) overexpressing transporters, such as ABCB1, ABCG4, and ABCC8. In addition, we assessed whether the morpholine KECH-18D could restore drug sensitivity by enhancing intracellular drug accumulation.

Materials and Methods: C-33A RCDDP cells were developed by stepwise cisplatin (CDDP) exposure. Cytotoxicity assays of nine morpholines were carried out to identify structural determinants of anticancer activity in the C-33A cell line. Combinatorial assays with morpholine KECH-18D and CDDP or paclitaxel (PTX) were performed to determine whether KECH-18D chemosensitizes and retains the drug in C-33A RCDDP and C-33A RPTX cells.

Results: C-33A RCDDP cells exhibited a 4.7-fold increase in CDDP resistance. C-33A RCDDP and C-33A RPTX cells both displayed cross-resistance patterns, but C-33A RTPX cells retained lower levels of the drug than C-33A RCDDP cells. Furthermore, KECH-18D maintained strong cytotoxicity against chemoresistant cell lines and enhanced the cytotoxicity of CDDP and PTX against them. Notably, KECH-18D increased drug accumulation in C-33A RCDDP cells in a time-dependent manner, but not in C-33A RPTX cells.

Conclusion: In summary, C-33A RCDDP and C-33A RPTX cells developed different levels, and possibly mechanisms, of resistance. Because the morpholine KECH-18D resulted highly cytotoxic in both parental and chemoresistant cells, enhanced drug retention in C-33A RCDDP cells and increased the toxicity of CDDP or PTX in chemoresistant cells, KECH-18D is a promising scaffold for overcoming multidrug resistance by selectively modulating drug efflux-related and -unrelated phenotypes, though further studies are necessary to deep its mechanisms of action.

Published

2026-07-13

How to Cite

1.
Clemente-Soto AF, Cisneros-Hernández M, Duriez-Tizoc NL, Bernal-Reynaga R, Maldonado-Domínguez M, Romero-Ávila M, et al. Morpholine KECH-18D Restores Drug Sensitivity and Differentially Modulates Efflux Phenotypes in Cisplatin- and Paclitaxel-Resistant Cervical Cancer Cells. Asian Pac J Cancer Biol [Internet]. 2026 Jul. 13 [cited 2026 Jul. 14];11(3):705-12. Available from: https://waocp.com/journal/index.php/apjcb/article/view/2215

Issue

Section

Research Articles/ Original Work